Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη του λειτουργικού ρόλου του ογκοκατασταλτικού γονιδίου CYLD στον καρκίνο του μαστού

Abstract

dc:description

The CYLD protein is a deubiquitinase that acts as a negative regulator of the NF-κB, JNK and p38 pathways. CYLD is predominantly a cytoplasmic protein of 956 amino acids. It contains three CAP-Gly domains at its N-terminus, that contribute to its interaction with the microtubules. The deubiquitinase catalytic domain is located at the C-terminus. CYLD was initially identified as a tumor suppressor protein that is causally associated with the development of skin appendage tumors. Since then, it has been involved in the growth suppression of different types of cancer cells, including colon, liver, lung, melanoma and breast. Its role in breast cancer is supported by its ability to inhibit the aggressive growth of BT549 breast cancer cell line by inducing apoptosis. In addition, the Cyld gene has been placed in the 5% of the major genes, whose expression levels show a significant reduction in subpopulations of breast cancer cases. This dissertation demonstrated the in vivo role of CYLD in mammary gland carcinogenesis in transgenic mice. The significant contribution of CYLD inactivation to increased and accelerated tumorigenesis in the mammary gland was shown after administration of the chemical carcinogen DMBA or the overexpression of the ErbB2 oncogene. Furthermore, the involvement of CYLD in the process of epithelial to mesenchymal transition (EMT), a process that is considered responsible for the invasion and metastasis of cancer cells as well as for resistance to chemotherapeutic approaches, was demonstrated and analyzed. The suppression of CYLD expression by RNA interference or inactivation by CRISPR-Cas9-mediated mutagenesis, led to an impressive induction of the TGFβ signaling pathway and consequently to activation of the EMT program. Finally, the role of cis and trans transcription factors as well as epigenetic modifications in the regulation of CYLD expression in breast epithelial cell lines was investigated. The ability of deacetylase inhibitors as well as the PPARγ nuclear hormone receptor to induce Cyld gene transcription was observed and CYLD was identified as a mediator of troglitazone-induced cytotoxicity towards breast cancer cells lines. The results of this dissertation demonstrated the important role of CYLD in the promotion of oncogene and carcinogen-induced breast carcinogenesis as well as its involvement in signal transduction mechanisms that promote EMT. These results could be exploited for the development of new therapeutic approaches and the control of resistance in existing chemotherapeutic approaches. Moreover, the usefulness of CYLD as a potential predictive biomarker for breast cancer has emerged.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Pseftogas, Athanasios
  • Ψευτογκάς, Αθανάσιος

Subjects

dc:subject × 8

Rights

dc:rights
Statement dc:rights
  • BY_NC_ND
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/42749

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Pseftogas, Athanasios; Ψευτογκάς, Αθανάσιος. Μελέτη του λειτουργικού ρόλου του ογκοκατασταλτικού γονιδίου CYLD στον καρκίνο του μαστού. Aristotle University Of Thessaloniki (AUTH), 2018. http://hdl.handle.net/10442/hedi/42749